Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Conditions
Glioblastoma, IDH-wildtype · Glioblastoma · Glioblastoma Multiforme · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype · GBM · Astrocytoma · Astrocytoma, IDH-Mutant
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Henry Ford Hospital, Detroit, Michigan, United States
Contact: Principal Investigator (Tobias Walbert, MD, PhD, MPH)Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States
Contact: Study coordinator (Nurse Navigators) · cancerclinicaltrials@cumc.columbia.edu · 212-342-5162Contact: Principal Investigator (Maria Diaz, MD)Duke University, Durham, North Carolina, United States
Contact: Principal Investigator (Annick Desjardins, MD, FRCPC)The Cleveland Clinic, Cleveland, Ohio, United States
Contact: Principal Investigator (David Peereboom, MD)Brown University Health/Rhode Island Hospital, Providence, Rhode Island, United States
Contact: Principal Investigator (Eric Wong, MD)UT MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Carlos Kamiya Matsuoka, MD)University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
Contact: Principal Investigator (Howard Colman, MD, PhD)
Study leads
Howard Colman, MD, PhD
Principal Investigator
Huntsman Cancer Institute/ University of Utah